Sector Expert: Douglas Loe

Euro Pacific Canada

Image: Douglas Loe

Douglas Loe, healthcare equity analyst with Euro Pacific Canada, brings more than a decade of experience to financial analysis in the global drug development, medical technology, healthcare services and specialty pharmaceutical sectors. Loe has been recognized as one of Canada's top healthcare analysts by the StarMine Analysts Awards, based on the quality of his recommendations to institutional investors. With his extensive knowledge of the healthcare industry, Loe analyzes and publishes his views on trends in the sector and interprets them within the context of a diversified suite of companies under coverage, many of which locked in substantial returns for investors over the last several quarters. He holds a Ph.D. in biochemistry.



Recent Interviews

A Bucket of Canadian Stocks Set to Soar in 2016: Euro Pacific Canada's Doug Loe (1/13/16)
google-IBB.630

The new year is off to a turbulent start, with indices across all markets, including biotech, sliding downward in the face of headwinds from China. Canadian healthcare stocks offer a windbreak for biotech investors, however, especially if they select a diversified basket across the various sectors. In this interview with The Life Sciences Report, Euro Pacific Canada's Doug Loe details a basket of Canadian companies that offer shelter from the storm.

Doug Loe: Canada Has Earned Its Spot in the Biotech All-Star Team Photo (12/18/14)
canadianflagsnow580

Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences Report, Loe gives the Canadian life sciences industry an upbeat prognosis, and offers ideas on companies that could realize generous returns in the sector in 2015.

Recent Quotes

— Douglas Loe, Echelon Growth Partners (11/2/16)
more >

— Douglas Loe, Echelon Growth Partners (9/28/16)
more >

"In Q4 FY15, CPHR exceeded our product and royalty revenue projections."

— Douglas Loe, Euro Pacific Canada (2/24/16)
more >

"We are projecting Q4 FY15 EBITDA/margin for CPHR of $2.8M/30.1%."

— Douglas Loe, Euro Pacific Canada (2/22/16)
more >

"CPHR submitted its new drug submission to Health Canada for Sitavig."

— Douglas Loe, Euro Pacific Canada (2/16/16)
more >

"Our price target on CPHR corresponds to a one-year return of 233.8%."

— Douglas Loe, Euro Pacific Canada (1/22/16)
more >

"If CPHR's forthcoming quarters exhibit dermatology product sales growth as robust as Q4/15, the company is poised for a valuation rebound."

The Life Sciences Report Interview with Doug Loe (1/13/16)
more >

"CPH received Canadian approval for Beteflam."

— Douglas Loe, Euro Pacific Canada (12/7/15)
more >

more comments

"Our price target on CPHR corresponds to a one-year return of 156%."

— Douglas Loe, Euro Pacific Canada (11/5/15)
more >

"The first group was enrolled for RP's Phase 1 trial in damaged skin."

— Douglas Loe, Euro Pacific Canada (10/20/15)
more >

"RP has been cleared for a Phase 1 RCS-01 trial for skin rejuvenation."

— Douglas Loe, Euro Pacific Canada (9/2/15)
more >

"RP commenced its Phase 1/2 ReaCT trial, enrolling its first patient."

— Douglas Loe, Euro Pacific Canada (7/2/15)
more >

"We are initiating coverage on RP with a Speculative Buy rating."

— Douglas Loe, Euro Pacific Canada (4/20/15)
more >

fewer comments


Due to permission requirements, not all quotes are shown.